SEARCH

SEARCH BY CITATION

References

  • 1
    Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006; 1: 397403.
  • 2
    Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 248798.
  • 3
    Ogawa Y, Tobinai K, Ogura M et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed and refractory multiple myeloma. Cancer Sci 2008; 99: 1404.
  • 4
    Miyakoshi S, Kami M, Yuji K et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107: 34924.
  • 5
    Gotoh A, Ohyashiki K, Oshimi K et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “lung injury by bortezomib” joint committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int J Hematol 2006; 84: 40612.
  • 6
    Narimatsu H, Hori A, Matsumura T et al. Cooperative relationship between pharmaceutical companies, academia and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan. J Clin Oncol 2008; 26: 58203.
  • 7
    FDA Guidance for industry, development and use of risk minimization action plans, March 2005. [Cited 22 Feb 2013.] Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071616.pdf.
  • 8
    ICH: Harmonization tripartite guideline, pharmacovigilance planning, E2E, November 2004. [Cited 22 Feb 2013.] Available from URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf.
  • 9
    Schwaiblmair M, Behr W, Haeckel T et al. Drug induced interstitial lung disease. Open Respir Med J 2012; 6: 6374.
  • 10
    Papiris SA, Triantafilldou C, Kolilekas L et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf 2010; 33: 53958.
  • 11
    White DA, Camus P, Endo M et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396403.
  • 12
    Maroto JP, Hudes G, Dutcher JP et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29: 17506.
  • 13
    Gemma A. Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med Sch 2009; 76: 48.
  • 14
    Pharmaceuticals and Medical Devices Agency, Reports on Iressa Tablets 250 prospective study (special investigation). Pharmaceuticals and Medical Devices Agency Safety Information. No. 206, Oct 2004. [Cited 05 Jun 2006.] Available from: http://www.pmda.go.jp/english/service/pdf/precautions/PMDASI-206.pdf.
  • 15
    Cohen MH, Williams GA, Sridhara R et al. FDA drug approval summary: Gefitinib ‘ZD1839) (Iressa) tablets. Oncologist 2003; 8: 3036.
  • 16
    Nakagawa K, Kudoh S, Ohe Y et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 2012; 7: 1296303.
  • 17
    Reck M, van Zandwijk N, Gridelli C et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceba Lung Cancer Survival Treatment study. J Thorac Oncol 2010; 5: 161622.
  • 18
    Azuma A, Hagiwara K, Kudoh S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. Am J Respir Crit Care Med 2008; 177: 13978.
  • 19
    Horiuchi-Yamamoto Y, Gemma A, Taniquchi H et al. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol 2013; 18: 7439.
  • 20
    Ishii T, Hagiwara K, Ikeda S et al. Association between genetic variations in surfactant protein D and emphysema, interstitial pneumonia, and lung cancer in a Japanese population. COPD 2012; 9: 40916.
  • 21
    Maruyama D, Watanabe T, Heike Y et al. Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. Int J Hematol 2008; 88: 396402.
  • 22
    Pitini V, Arrigo C, Altavilla G et al. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res 2007; 31: 10278.
  • 23
    Min CK, Lee S, Kim YJ et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 2006; 76: 2658.
  • 24
    Cullen SJ, Ponnappan S, Ponnappan U et al. Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation. Biochem Pharmacol 2010; 79: 70614.
  • 25
    Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. Int J Clin Oncol 2012; 17: 53441.